Passage Bio Q1 2025 net loss $15.4M; cash runway into Q1 2027; first FTD-GRN patient dosed at Dose 2

Passage BIO, Inc.

2025-Q1 EPS reported -$0.25

Net loss of $15.4M ($0.25 per share) vs $16.7M ($0.30 per share) in Q1 2024.
Cash, cash equivalents and marketable securities $63.4M as of Mar 31, 2025; funding expected into Q1 2027.
First FTD-GRN patient dosed with Dose 2 PBFT02; second patient enrolled; additional patients being evaluated.
Enrollment opened for FTD-C9orf72 patients in the upliFT-D study, targeting up to five symptomatic patients.
R&D expenses decreased to $7.7M from $11.5M; G&A expenses were $6.1M vs $6.5M year-over-year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.